



1642
Attorney Docket No. 037003-0280618
Client Ref. No. 1997-30-0568D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
OCT 29 2003
TECH CENTER 1600/2900

In re Application of: Hanna, et al.

Serial No: 09/853,580

Filed: May 14, 2001

Title: SYNERGISTIC COMPOSITION
AND METHODS FOR
TREATING NEOPLASTIC OR
CANCEROUS GROWTHS FOR
RESTORING OR BOOSTING
HEMATOPOIESIS

) Examiner: Gary B. Nickol

)

)

) Art Unit: 1642

)

Certificate of Mailing Under §1.10

) I, Patricia Munoz, hereby certify that this paper
or fee is being deposited with the United States
Postal Service as Express Mail Post Office to
Addressee service, Express Mailing Label No.
EL 989 437 616 US, under 37 C.F.R. § 1.10 on
the date indicated below and is addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 on this date.

) Date: Oct 22, 2003

By: Patricia Munoz
Patricia Munoz

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the information on the attached Form PTO-1449 be considered by the Office during the pendency of the above-entitled application, pursuant to 37 C.F.R. 1.97. In accordance with 37 C.F.R. 1.97(h), the filing of the Information Disclosure Statement shall not constitute an admission that any information cited therein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b). Please note that certain of these references were cited in the International Search Report for PCT/US98/18495 which is related to the subject application. A copy of the International Search Report is enclosed. In the interest of full and


complete disclosure to the Office, some or all of the art cited herein may not be considered by Applicant(s) or the Undersigned to be material under the standards of materiality defined in C.F.R. 1.56(b), enacted March 16, 1992, as amended September 8, 2000, and may merely be technical background which may be of interest to the Examiner.

In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

Since an Office Action on the merits has issued for this application, Applicants believe that a fee is due. Accordingly, please charge any fees that may be necessary to Deposit Account No. 03-3975, Order No. 037003-0280618. A duplicate copy of this transmittal is enclosed for accounting purposes.

Respectfully submitted,

Date: October 22, 2003


Suzanne L. Biggs
Registration No. 30,158 for

Thomas A. Cawley, Jr.
Registration No. 40,944
PILLSBURY WINTHROP LLP
1600 Tysons Boulevard
McLean, VA 22102
Telephone: (703) 905-2000
Fax Line: (703) 905-2500
Direct Line: (858) 509-4095

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280618	1997-30-0568D1

Applicant: Hanna, et al.

Appln. No.: 09/853,580

Filing Date: May 14, 2001

Examiner: Gary B. Nickol Group Art Unit: 1642

Date: October 22, 2003

Page **1** of **1**

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 5,585,103	12/1996	Raychaudhuri, et al. (<i>Previously submitted with IDS filed on May 14, 2001</i>)	424	278.1	RECEIVED
BR						OCT 28 2003
CR						
DR						
ER						
FR						
GR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclose	No
HR								
IR								
JR								
KR								

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

LR	Murphy, et al. Differential effects of growth hormone and prolactin on murine T cell development and function, The Journal of Experimental Medicine, 178:231-236 (1993)		
MR	Richards, et al., Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas, Cellular Immunology, 184:85-91 (1998)		
NR			
OR			
PR			
QR			

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.